Open AccessMonitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs
Author(s) -
Spyros I. Siakavellas,
John Goulis,
Spilios Manolakopoulos,
Christos Triantos,
Nikolaos Gatselis,
E. Tsentemidou,
Hariklia Kranidioti,
Κonstantinos Ζisimopoulos,
Christos Τsoulas,
George Ν. Dalekos,
George Papatheodoridis
Publication year - 2020
Publication title -
annals of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.886
H-Index - 33
eISSN - 1792-7463
pISSN - 1108-7471
DOI - 10.20524/aog.2020.0525
Subject(s) - medicine , hepatocellular carcinoma , concomitant , entecavir , diabetes mellitus , decompensation , cohort , discontinuation , cirrhosis , gastroenterology , hepatitis b , population , chronic hepatitis , lamivudine , immunology , virus , environmental health , endocrinology
Long-term monotherapy with nucleos(t)ide analogs (NAs) represents the treatment option for the majority of patients with chronic hepatitis B (CHB), an aging population with a greater likelihood of comorbidities. We assessed the prevalence of concurrent non-hepatic diseases and the safety monitoring in a large cohort of CHB patients receiving NAs and their potential impact on disease outcomes.